Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).

ABSTRACT:

Background

The phase 3 MPACT trial in patients with metastatic pancreatic cancer demonstrated superior efficacy of nab-paclitaxel (nab-P) + gemcitabine (Gem) vs Gem monotherapy for all endpoints examined including overall survival, the primary endpoint. In the MPACT trial, patients were treated until progressive disease (PD) or unacceptable toxicity. The current exploratory analysis investigated outcomes of patients from the MPACT trial who were treated until PD, in order to understand how to maximize treatment benefit from nab-P + Gem.

Methods

The trial design has been described in detail previously. Progressive disease was determined by the investigator on the basis of radiological imaging.

Results

Among patients who were treated until PD, overall survival was signi

SUBMITTER: Vogel A 

PROVIDER: S-EPMC5073820 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature